Abstract | INTRODUCTION: AREAS COVERED: In recent years, analysis of large series from international databases (mainly from the European Bone Marrow Transplantation [EBMT] database) has improved knowledge about HSCT in IBMFS. This review, following a thorough Medline search of the pertinent published studies, reports the most recent data on HSCT in IBMFS. EXPERT OPINION: Despite the common features, IBMFS are very different in their manifestations and in the occurrence and management of HSCT complications. Thus, a 'disease-specific' HSCT using an optimized conditioning regimen based on the characteristics of the disease is essential for achieving long-term survival. The phenotypical heterogeneity associated with extramedullary abnormalities has to be carefully evaluated before HSCT because transplantation may only correct impaired hematopoiesis. HSCT may be associated with the risk of treatment-related mortality and with significant early and late morbidity. For these reasons, the benefits should be carefully weighed against the risks.
|
Authors | Filomena Pierri, Maura Faraci, Stefano Giardino, Carlo Dufour |
Journal | Expert review of hematology
(Expert Rev Hematol)
Vol. 14
Issue 10
Pg. 911-925
(10 2021)
ISSN: 1747-4094 [Electronic] England |
PMID | 34488529
(Publication Type: Journal Article, Review)
|
Topics |
- Congenital Bone Marrow Failure Syndromes
- Hematopoietic Stem Cell Transplantation
(adverse effects, methods)
- Humans
- Leukemia, Myeloid, Acute
(etiology)
- Myelodysplastic Syndromes
(genetics, therapy)
- Transplantation Conditioning
(methods)
|